Anti-hMC2RL1 Functionalized Gold Nanoparticles for Adrenocortical Tumor Cells Targeting and Imaging

Area of Science:

• Oncology
• Nanotechnology
• Immunology

Background:

• Adrenocortical carcinoma (ACC) has a low cure rate due to factors like TP53 mutations, late diagnosis, and limited treatment options.
• Current diagnostic and therapeutic strategies for ACC require improvement to enhance patient outcomes.

Purpose of the Study:

• To develop novel gold nanoparticle (AuNP) probes for specifically targeting adrenocortical carcinoma (ACC) cells.
• To evaluate the potential of AuNP-antibody conjugates for ACC diagnostics and targeted therapy.

Main Methods:

• Immunohistochemistry was used to validate an antibody targeting the human melanocortin receptor 2 (hMC2R).
• The antibody was conjugated to fluorescein isothiocyanate (FITC)-labeled gold nanoparticles (AuNPs).
• Direct immunofluorescence assays were performed on the H295R ACC cell line to assess probe specificity and background.

Main Results:

• The developed antibody and a commercial control antibody specifically targeted cells expressing hMC2R.
• FITC-labeled AuNP probes demonstrated specific recognition of hMC2R-expressing cells with minimal background.
• The probes successfully targeted ACC cells in vitro.

Conclusions:

• Gold nanoparticle (AuNP) probes conjugated with specific antibodies can effectively target adrenocortical carcinoma (ACC) cells.
• These AuNP probes hold potential for enhancing ACC tumor diagnostics through imaging.
• AuNP-antibody conjugates may serve as a platform for targeted drug delivery in ACC therapy.